Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 5:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: salmeterol Clear all
Completed Phase 4 Interventional Results available

Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep

NCT00731770
View directory record Official record
Conditions
COPD
Interventions
Advair 250, Placebo- matched, Placebo, Advair 250 - matched
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
45 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 15, 2026, 5:41 PM EDT
Completed Not applicable Interventional Results available

The Effect of Salmeterol on Eosinophil (EOS) Function

NCT00214019
View directory record Official record
Conditions
Allergic Asthma
Interventions
salmeterol, Fluticasone, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Sep 15, 2026, 5:41 PM EDT
Completed Phase 4 Interventional Results available

A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial

NCT01696214
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone 250 mg/salmeterol 50 mg, Montelukast 10mg, Theophylline 400 mg, ipratropium
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 15, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Results available

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

NCT00529529
View directory record Official record
Conditions
Asthma
Interventions
Indacaterol 300 μg, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
56
States / cities
Glendale, Arizona • Phoenix, Arizona • Encinitas, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2011 · Synced Sep 15, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component

NCT02164539
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF, UMEC, VI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Newport Beach, California • San Diego, California • Upland, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 15, 2026, 5:41 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects

NCT02568319
View directory record Official record
Conditions
Central Abdominal Bulging
Interventions
LIPO-202, Placebo
Drug
Lead sponsor
Neothetics, Inc
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
6
States / cities
Encinitas, California • Manhattan Beach, California • Aventura, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Sep 15, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

NCT01772134
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
13
States / cities
Jasper, Alabama • Clearwater, Florida • Ormond Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Sep 15, 2026, 5:41 PM EDT
Completed Phase 4 Interventional Results available

Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study

NCT01110200
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
ADVAIR DISKUS 250/50 mg BID, SEREVENT 50 mcg BID
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 85 Years
Enrollment
639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
74
States / cities
Birmingham, Alabama • Florence, Alabama • Mobile, Alabama + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 15, 2026, 5:41 PM EDT
Terminated Not applicable Interventional Results available

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations

NCT00706446
View directory record Official record
Conditions
Asthma
Interventions
tiotropium bromide, Salmeterol, Formoterol, Fluticasone propionate, budesonide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 15, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Results available

A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma

NCT00441441
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate, fluticasone propionate/salmeterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 11 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Huntington Beach, California • Long Beach, California • Riverside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 15, 2026, 5:41 PM EDT
Completed Not applicable Interventional Results available

Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program

NCT02024204
View directory record Official record
Conditions
Lung Diseases, Medication Compliance
Interventions
Fluticasone propionate 230mcg for 3 Months, Current Treatment or no treatment, Salmeterol 21mcg for 3 Months
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 15, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Different Doses of Indacaterol

NCT01079130
View directory record Official record
Conditions
Asthma
Interventions
Indacaterol, Salmeterol, Placebo to Indacaterol, Placebo to Salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
71
States / cities
Glendale, Arizona • Scottsdale, Arizona • Encinitas, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Sep 15, 2026, 5:41 PM EDT
Terminated Phase 4 Interventional

Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS)

NCT00471809
View directory record Official record
Conditions
Asthma
Interventions
Budesonide + Salmeterol + Azithromycin, Budesonide + Salmeterol + Montelukast, Budesonide + Salmeterol + Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
6 Years to 17 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Sep 15, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma

NCT02433834
View directory record Official record
Conditions
Asthma
Interventions
Glycopyrronium MDI, Serevent Diskus 50 μg, Placebo
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
43
States / cities
Birmingham, Alabama • Anaheim, California • Bakersfield, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 15, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

NCT01312961
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy, Albuterol, Levalbuterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
50
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Sep 15, 2026, 5:41 PM EDT
Completed No phase listed Observational Results available

Pharmacogenetics of b2-Agonists in Asthma.

NCT00708227
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
10 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Sep 15, 2026, 5:41 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Advair HFA in Healthy and HAPE Predisposed Subjects

NCT06040268
View directory record Official record
Conditions
Altitude Edema
Interventions
Advair HFA, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 15, 2026, 5:41 PM EDT
Not listed Phase 4 Interventional

Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography

NCT01361984
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD, Emphysema, Chronic Bronchitis
Interventions
Nebulized arformoterol, Salmeterol
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Sep 15, 2026, 5:41 PM EDT
Terminated Not applicable Interventional

Evaluating Genes in Sputum to Measure Drug Response in COPD

NCT00233051
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
Interventions
Salmeterol or Salmeterol/Fluticasone
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 15, 2026, 5:41 PM EDT
Completed Phase 4 Interventional

Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID

NCT00235053
View directory record Official record
Conditions
Asthma, Candidiasis, Oral, Voice Disorders
Interventions
fluticasone/salmeterol DISKUS 250/50
Drug
Lead sponsor
Allergy & Asthma Medical Group & Research Center
Other
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 15, 2026, 5:41 PM EDT
Completed Not applicable Interventional Results available

Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes

NCT00521222
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone with salmeterol, Fluticasone HFA, Ipratropium HFA, Albuterol HFA
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Hackensack, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Sep 15, 2026, 5:41 PM EDT
Suspended Not applicable Interventional

A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic Fibrosis

NCT00005110
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Salmeterol, Albuterol
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
5 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 15, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Results available

Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler

NCT02980133
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate, Fluticasone Propionate/Salmeterol, Placebo MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
77
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 15, 2026, 5:41 PM EDT
Recruiting Phase 4 Interventional

Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

NCT01225913
View directory record Official record
Conditions
Asthma
Interventions
fluticasone/salmeterol in all asthmatics, budesonide/formoterol or fluticasone/salmeterol in all asthmatics
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
10 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 15, 2026, 5:41 PM EDT